On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...

Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...